%0 Journal Article
%T Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications
%A Bobby Liaw
%A Catherine He
%A Che-Kai Tsao
%A John Sfakianos
%A Matthew D. Galsky
%A William K. Oh
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2017
%R 10.1177/1758834016687261
%X Renal cell cancer (RCC) continues to be among the most lethal malignancies in the USA. Introduction of anti-vascular epidermal growth factor receptor tyrosine kinase inhibitors over a decade ago resulted in improvement in disease outcomes, but further development of new therapies largely stagnated for many years. More recently, a better understanding of disease biology and treatment-resistance patterns has led to a second renaissance in drug development, with the anti-programmed cell death protein 1 immune checkpoint inhibitor, nivolumab, paving the way for additional therapies entering clinical trial testing in the treatment of RCC
%K clear cell
%K immunotherapy
%K renal cell carcinoma
%K targeted therapies
%K vascular epidermal growth factor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405995/